Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02496468
Other study ID # DZL_DA_AA-1
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 2013
Est. completion date December 2023

Study information

Verified date December 2020
Source Klinikum der Universitaet Muenchen
Contact Esther Zeitlmann, Diplom
Phone +49894400
Email esther.zeitlmann@med.uni-muenchen.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Despite its common occurrence, still little is known about pathomechanisms determining different wheeze and asthma trajectories and phenotypes in children, and those beginning in adulthood. Therefore, deciphering underlying determinants for different childhood and adult asthma phenotypes is urgently needed to develop personalized treatment approaches targeting distinct underlying mechanisms. Thereby, secondary prevention early in the disease process can also be achieved. The decoding of such mechanisms and their translation to the individual patient is the aim of the Disease Area Asthma Allergy of the 'German Centre for Lung Research' (DZL).


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany University Children's Hospital Cologne, Department of Paediatric Allergology and Pneumology Cologne
Germany Medizinische Hochschule Hannover, Biomedical Research in Endstage and Obstructive Lung Disease Hannover
Germany Universitaetsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin, Airway Research Center North Luebeck
Germany Klinik für Kinder- und Jugendmedizin, Universitaetsklinikum Giessen und Marburg GmbH, Universities of Giessen and Marburg Lung Center Marburg
Germany Klinikum der Universitaet Muenchen, Comprehensive Pulmonary Center Munich Munich

Sponsors (8)

Lead Sponsor Collaborator
Klinikum der Universitaet Muenchen Airway Research Center North, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Comprehensive Pulmonary Center Munich, German Center for Lung Research, German Federal Ministry of Education and Research, Translational Lung Research Center Heidelberg, Universities of Giessen and Marburg Lung Center

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of asthma Study participants will be assessed with regard to their development of asthma. At baseline and during yearly follow-ups up to 2 years
Primary Prevalence of transient preschool wheeze Study participants will be assessed with regard to their development of transient preschool wheeze. At baseline and during yearly follow-ups up to 2 years
Secondary Prevalence of atopic sensitization The prevalence of atopic sensitization will be measured by the detection of specific immunoglobin E against common aeroallergens. At baseline and during yearly follow-ups up to 2 years
Secondary Lung function Study participants will be assessed with regard to lung function parameters (as measured by spirometry/bodyplethysmography and multiple-breath washouts (MBW)). At baseline and during yearly follow-ups up to 2 years
Secondary Levels of exhaled nitric oxide Levels of exhaled nitric oxide (eNO) will be measured by chemoluminescence analyzers in combination with ultrasound-based flow measurement. At baseline and during yearly follow-ups up to 2 years
Secondary Frequency of acute exacerbations during previous 12 months The frequency of acute exacerbations during previous 12 months will be assessed by questionnaires. At baseline and during yearly follow-ups up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device